Combined therapy for muscular diseases

A kit comprising:

• a GDF5 pathway-activating substance;
• and
• at least one other active ingredient,
• wherein the GDF5 pathway-activating substance is selected from a synthetic or recombinant GDF5 peptide, and a vector comprising a nucleic acid encoding GDF5;
• wherein the at least one other active ingredient comprises an isolated antisense oligonucleotide (AON) capable of inducing an exon-skipping in a dystrophin pre-mRNA and a Duchenne muscular dystrophy therapeutic viral vector encoding:
• an antisense oligonucleotide able to induce exon-skipping within a dystrophin pre-mRNA;
• a dystrophin gene-editing means;
• or
• a functional dystrophin protein.